News & Updates
Filter by Specialty:
First data from Vaccine Allergy Safety clinics reaffirm COVID-19 vaccine safety
First data from Vaccine Allergy Safety (VAS) clinics in Hong Kong show that a majority of high-risk patients can receive coronavirus disease 2019 (COVID-19) vaccination safely, with no immediate allergic reactions.
First data from Vaccine Allergy Safety clinics reaffirm COVID-19 vaccine safety
01 Mar 2022
Corticosteroid-remdesivir combo suppresses secondary infections in severe COVID-19
The combination of corticosteroid (CS) therapy with remdesivir (RDV) has noninferior survival outcomes relative to CS monotherapy in patients hospitalized with the coronavirus disease 2019 (COVID-19), reports a recent study.
Corticosteroid-remdesivir combo suppresses secondary infections in severe COVID-19
01 Mar 2022
Early ivermectin does not prevent progression to severe COVID-19
The early addition of ivermectin to standard of care (SoC)* in high-risk patients with mild-to-moderate COVID-19 did not prevent progression to severe disease compared with SoC alone, according to results of the I-TECH** trial conducted in Malaysia.
Early ivermectin does not prevent progression to severe COVID-19
28 Feb 2022
Hepatitis C reinfection rates up in direct-acting antiviral era
There is an increased rate of hepatitis C virus (HCV) reinfection among people who inject drugs after the scale-up of direct-acting antivirals, reports a recent Scotland study.
Hepatitis C reinfection rates up in direct-acting antiviral era
26 Feb 2022
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
Use of famotidine in the treatment of outpatients with mild-to-moderate COVID-19 is safe and well tolerated, leading to rapid resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity, according to the results of a phase II trial.
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
25 Feb 2022
Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients
Patients with non-severe coronavirus disease 2019 (COVID-19) who have worse glycaemic status are more likely to deteriorate clinically, but glycaemic status does not adversely impact neutralizing antibody (NAb) responses, researchers from the University of Hong Kong have shown.
Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients
24 Feb 2022
Booster dose effective in reducing COVID-19 across ages in adults
The risk of COVID-19 is substantially reduced in adults who receive a third “booster” dose of the BNT162b2 vaccine regardless of their age, according to a study from Israel.
Booster dose effective in reducing COVID-19 across ages in adults
23 Feb 2022
Intranasal influenza-based booster induces mucosal immunity against SARS-CoV-2 in animal model
Research from the University of Hong Kong (HKU) demonstrates that intranasal influenza-based booster vaccination following PD1-based receptor-binding domain (RBD) DNA vaccine induces mucosal and systemic immunity for effective prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both upper and lower respiratory systems of mice.